Market revenue in 2023 | USD 23.3 million |
Market revenue in 2030 | USD 102.9 million |
Growth rate | 23.6% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.09% in 2023. Horizon Databook has segmented the Norway cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
With diverse capabilities in treatments & diagnostics in fields, such as cancer and neurosciences, Norway has a developing pharmaceutical sector. Due to its long history in the biomedical sciences, Norway is considered to be a lucrative market for businesses looking to set up a base or to collaborate.
In addition, Norway’s strategic location and access to global markets make it an attractive destination for pharmaceutical companies looking to expand their international presence. Moreover, CDMOs operating in Norway can leverage these advantages to offer services to domestic & international clients, further driving growth in the pharmaceutical outsourcing sector.
For instance, in September 2022, NextPharma finalized a deal to acquire the Takeda manufacturing facility located in Asker, Norway. This addition marks a strategic expansion for NextPharma, complementing its existing industrial network. In addition, NextPharma enhances its portfolio by incorporating healthcare logistics services in the DACH region.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Norway cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account